Citigroup
FDMT icon

Citigroup’s 4D Molecular Therapeutics FDMT Stock Holding History

Citigroup’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.08M Buy
75,204
+5,992
+9% +$78K ﹤0.01% 3259
2026
Q2 		$921K Buy
69,212
+43,032
+164% +$419K ﹤0.01% 3514
2026
Q1 		$244K Buy
26,180
+13,521
+107% +$118K ﹤0.01% 3921
2025
Q4 		$94.9K Buy
12,659
+9,164
+262% +$93K ﹤0.01% 4347
2025
Q3 		$30.4K Sell
3,495
-19,301
-85% -$115K ﹤0.01% 4656
2025
Q2 		$84.6K Sell
22,796
-62,284
-73% -$219K ﹤0.01% 4492
2025
Q1 		$275K Sell
85,080
-8,541
-9% -$40.2K ﹤0.01% 4007
2024
Q4 		$521K Buy
93,621
+3,219
+4% +$25.3K ﹤0.01% 3791
2024
Q3 		$977K Buy
90,402
+7,592
+9% +$126K ﹤0.01% 3280
2024
Q2 		$1.74M Sell
82,810
-70,474
-46% -$1.77M ﹤0.01% 2457
2024
Q1 		$4.88M Buy
153,284
+111,976
+271% +$2.86M ﹤0.01% 1721
2023
Q4 		$837K Sell
41,308
-13,391
-24% -$176K ﹤0.01% 2979
2023
Q3 		$696K Sell
54,699
-3,458
-6% -$57.8K ﹤0.01% 2799
2023
Q2 		$1.05M Sell
58,157
-53,521
-48% -$985K ﹤0.01% 2813
2023
Q1 		$1.92M Buy
111,678
+85,862
+333% +$1.67M ﹤0.01% 2050
2022
Q4 		$573K Buy
25,816
+15,922
+161% +$246K ﹤0.01% 3067
2022
Q3 		$80K Sell
9,894
-2,343
-19% -$21.2K ﹤0.01% 4197
2022
Q2 		$85K Sell
12,237
-16,358
-57% -$159K ﹤0.01% 4296
2022
Q1 		$432K Sell
28,595
-54,577
-66% -$857K ﹤0.01% 3611
2021
Q4 		$1.82M Buy
83,172
+80,369
+2,867% +$1.97M ﹤0.01% 2697
2021
Q3 		$76K Buy
2,803
+1,218
+77% +$34.7K ﹤0.01% 4525
2021
Q2 		$38K Buy
1,585
+217
+16% +$6.64K ﹤0.01% 4942
2021
Q1 		$59K Buy
+1,368
New +$60.6K ﹤0.01% 4609

Other funds holding FDMT

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Perigon Wealth Management
Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Citigroup's FDMT Position: Q3 2026 in Review

Citigroup increased its 4D Molecular Therapeutics (FDMT) stake by 8.7% in Q3 2026, buying an estimated $78K and bringing the position to 75,204 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

Citigroup first reported a position in FDMT in Q1 2021 and has held it in 23 quarters since. The position peaked at $4.88M in Q1 2024. 40 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Citigroup held 75,204 shares of 4D Molecular Therapeutics worth $1.08M as of Q3 2026.
  • Citigroup bought 5,992 4D Molecular Therapeutics shares in Q3 2026, an estimated $78K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3259 holding.
  • Citigroup first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 23 quarters since.
  • Citigroup's 4D Molecular Therapeutics position peaked at $4.88M in Q1 2024.
  • 40 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.